Editas Medicine Strengthens Executive Leadership Team with Appointment of Linea Aspesi as Chief People Officer
“Our people and our culture are critical ingredients for the success of our new strategy, and we are fortunate to have someone of Linea’s caliber and expertise in defining, shaping, and implementing talent strategies for accelerated company growth. I look forward to working with Linea and the Leadership Team to help drive our talented team towards our goal of becoming a commercial-stage organization and transforming the lives of people living with serious diseases,” said Gilmore O’Neill, M.B.,
“People are truly the foundation to making any company successful. With our new strategy, we have a unique opportunity to reengage with and inspire our talented team to develop and grow into the future. I am excited to partner with our Leadership Team and our employees to make an impact in the lives of patients around the world,” said
About
As a clinical-stage genome editing company,
Forward-Looking Statements
This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "target," "should," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials, and clinical development of the Company’s product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption “Risk Factors” included in the Company’s most recent Annual Report on Form 10-K, which is on file with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0a8f135a-e273-4d1f-b8af-89d322609647

Editas Medicine Contacts: MediaCristi Barnett (617) 401-0113 cristi.barnett@editasmed.com InvestorsRon Moldaver (617) 401-9052 ir@editasmed.com
Source: Editas Medicine, Inc.